Bio News
BioXcel Therapeutics has filed for bankruptcy protection and agreed to sell its assets to Teva Pharmaceuticals for $57.5 million (approximately 7.94 billion won). Teva was selected as the stalking-horse bidder to acquire BioXcel’s neuroscience assets. BioXcel will receive up to $67.5 million in milestone payments if the U.S. Food and Drug Administration approves BXCL501.
BIOBOOK TEAM
biobookmedia@biobook.co.krRoche’s New Drug for Uveitic Macular Edema Faces FDA Decision in July 2027
BMS Reports Concurrent Phase 3 Success in Idiopathic Pulmonary Fibrosis and Solid Tumors
Merck’s $1.3 trillion eye disease drug raises safety and efficacy concerns: “Limited competitiveness”
CHA Biotech Holds 24.23% Stake in CMG Pharmaceutical as Share Consolidation Reduces Its Share Count
Rural Development Administration Develops Two Molecular Markers to Identify Leaf Splitting in Squash
MFDS Begins Distribution of Internationally Certified Reference Materials, Including 24 New Items, for a Total of 882
